Cancer is defined as the abnormal growth of cells in the body. Cells located in any part of the body can turn cancerous and spread to other parts of the body. Liver cancer starts in the cells of the liver. Multiple kinds of cancer can form in the liver. Hepatocellular carcinoma is considered the most common liver cancer and starts in the hepatocyte. Several other types of liver cancer include hepatoblastoma and intrahepatic cholangiocarcinoma. These are considered to be less common. By the American Society of Clinical Oncology (ASCO), about 80% of adult primary liver cancers are hepatocellular carcinomas. Liver cancer diagnostics include techniques used for liver cancer identification and confirmation.
Philips and Siemens Healthcare GmbH- Notable Market Players in Liver Cancer Diagnostics Market
The Liver Cancer Diagnostics market majorly consists of the players such as Abbott, BioMerieux SA, F. HOFFMANN-LA ROCHE LTD., Illumina, Inc., Koninklijke Philips N.V., QIAGEN, Siemens Healthineers AG, THERMO FISHER SCIENTIFIC INC., GE Healthcare, Perspectum, Helio, Inc. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the Liver Cancer Diagnostics market:
| Year | News |
| Mar-22 | Illumina, Inc. launched TruSight oncology test for assessing multiple tumor genes and biomarkers. The TruSight test will soon begin its global launch in Europe, assesses the tumor genes and biomarkers to reveal the specific molecular profile of a patient’s cancer, helping to inform precision medicine decisions. |
| Dec-21 | Helio, Inc and its commercial partner, Fulgent Genetics, Inc. commercially launched HelioLiver, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer. The test detect HCC at its earliest stages thus, providing potential to enable more curative treatment options. |
| Nov-2021 | Perspectum entered into partnership with HepQuant to provide seamless delivery of HepQuant’s liver function assessment technology via Perspectum’s Contract Research Organization (CRO) services. The collaboration has enabled pharmaceutical companies sponsoring clinical trials for liver disease, including liver cirrhosis, nonalcoholic steatohepatitis (NASH), autoimmune liver diseases and liver cancer to receive both imaging and function testing expertise from Perspectum’s Pharma Solutions |
| Aug-2021 | Illumina, Inc. acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission’s ongoing regulatory review. There was no legal impediment to acquiring GRAIL in the US. The decision to make the acquisition and hold the companies separate permits the regulatory processes to proceed while safeguarding the life-saving, pro-competitive benefits of this vertical transaction without the deal expiring. |
| Jul-2021 | Perspectum announced the results for new prospective, observational, cohort study called Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing. In the study, Hepatica imaging technology was integrated with clinically actionable whole genome sequencing biomarkers and digital pathology results to derange the cancer care pathway. The study was funded as a part of the Innovate UK/UKRI Data to Early Diagnosis and Precision Medicine Challenge. |
| Jun-2021 | Koninklijke Philips N.V. entered into partnership with Elekta to advance comprehensive and personalized cancer care through precision oncology solutions. The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy. The cross-portfolio collaboration leveraged company’s capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties’ systems and software in order to drive precision in oncology. |
| May-2021 | GE Healthcare acquired Zionexa, a France-based in-vivo oncology and neurology biomarker developer to further develop molecular imaging agents for cancer treatment. As per the terms of the agreement, GE Healthcare got the right to develop and commercialise the Zionexa biomarkers and positron emission tomography (PET) imaging agent, Cerianna (fluoroestradiol F-18). |
| Apr-2021 | Siemens Healthineers AG acquired Varian Medical Systems, Inc. to create most comprehensive cancer care portfolio in the industry. he acquisition was previously announced on August 2, 2020. The two companies are building on a strategic partnership called EnVision, which sets out to create a digital, diagnostic and therapeutic ecosystem that includes treatment management. |
| Nov-20 | Helio, Inc and its commercial partner, Fulgent Genetics, Inc. announced new data at AASLD demonstrating the performance of HelioLiver in detecting early hepatocellular carcinoma (HCC). At 91% specificity, the sensitivity of HelioLiver was 76% in early-stage HCC and 85% in overall HCC1, demonstrating superior performance over alpha fetoprotein (AFP) alone and the GALAD model.The test reveals new findings underscore HelioLiver’s potential to detect liver cancer early and ultimately save lives. |
